Signant Acquires DSG
Signant adds DSG’s solution suite to its own capabilities to grow CRO and sponsor services.
Signant Health has acquired DSG – a 20-year-old provider of electronic data capture (EDC) and direct data capture (DDC) technology for site-based and decentralized clinical trials. DSG will become a Signant company, and Signant will add the DSG capabilities to its digital solutions for clinical trials, including eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics.
The DSG solution suite was chosen based on the following criteria: (1) ease of use – where sites in particular provided positive feedback; (2) operational efficiency – combines rapid study start up times with workflow tools and remote SDV capabilities; (3) flexibility –accommodates the requirements of both simple and complex study designs; and (4) customer support.
“We believe DSG is the industry’s best kept secret. We are excited to welcome the DSG team to Signant, enabling us to extend our product suite to include comprehensive EDC/DDC capabilities,” said Roger Smith, Signant’s chief executive officer.
Reference: Signant Acquires DSG to Enhance Its eClinical Solution Suite for Traditional and Decentralized Clinical Trials. PHILADELPHIA, PA – July 17, 2023. https://www.signanthealth.com/company/newsroom/item/signant-acquires-dsg-to-enhance-its-eclinical-solution-suite-for-traditional-and-decentralized-clinical-trials/
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
